EU/3/19/2168

Table of contents

About

On 28 June 2019, orphan designation EU/3/19/2168 was granted by the European Commission to Khondrion B.V., the Netherlands, for (S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidine-3-yl)chroman-2-carboxamide hydrochloride (also known as KH176) for the treatment of maternally inherited diabetes and deafness.

Key facts

Active substance
(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidine-3-yl)chroman-2-carboxamide hydrochloride
Disease / condition
Treatment of maternally-inherited diabetes and deafness
Date of first decision
28/06/2019
Outcome
Positive
EU designation number
EU/3/19/2168

Sponsor's contact details

Khondrion B.V.
Philips Van Leydenlaan 15
6525 EX Nijmegen
The Netherlands 
Tel. +31 243 617 505
E-mail: info@khondrion.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating